Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5851166 | 0.85 | P2RY12 (0.61) | KMT2AMEN1ALDH1A1NPSR1LMNA | |
| SCHEMBL5849182 | 0.85 | KMT2A (0.53) | KMT2AMEN1ALDH1A1NPSR1LMNA | |
| SCHEMBL5849157 | 0.85 | P2RY12 (0.60) | KMT2AMEN1ALDH1A1NPSR1LMNA | |
| SCHEMBL7064279 | 0.77 | MEN1 (0.65) | KMT2AMEN1ALDH1A1NPSR1LMNA | |
| SCHEMBL5849656 | 0.73 | KMT2A (0.44) | KMT2AMEN1ALDH1A1NPSR1LMNA | |
| SCHEMBL3404456 | 0.73 | KMT2A (0.72) | KMT2AMEN1ALDH1A1NPSR1LMNA | |
| SCHEMBL7059743 | 0.73 | SMN1; SMN2 (0.58) | KMT2AMEN1ALDH1A1NPSR1LMNA | |
| SCHEMBL16636980 | 0.73 | KMT2A (0.74) | KMT2AMEN1ALDH1A1NPSR1LMNA | |
| SCHEMBL5849659 | 0.73 | KMT2A (0.41) | KMT2AMEN1ALDH1A1NPSR1LMNA | |
| SCHEMBL7062968 | 0.72 | MEN1 (0.61) | KMT2AMEN1ALDH1A1NPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030153556-A1 | Piperazine and homopiperazine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153556-A1 | Piperazine and homopiperazine compounds | HAMP, MPL, F2 | KMT2A 1823/4885MEN1 2603/4885ALDH1A1 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.